SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology ($GSIT) is trending due to news highlighting their Compute-In-Memory APU achieving GPU-class AI performance with significantly lower energy costs, sparking community interest in its potential to compete with industry giants like NVDA. Discussions revolve around the APU's performance and energy efficiency, with some viewing GSIT as an overlooked player in the AI and drone sectors due to its exposure to high-speed memory solutions and defense contracts.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending after announcing plans to explore rare earth production at its U.S. mining sites, potentially making it a key player in America's push for critical mineral independence. The community is discussing the company's strategic shift from steel to strategic minerals, with some believing it's a smart move given China's tightening export controls, while others express skepticism and focus on debt reduction.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

REPL is experiencing a surge driven by news of the FDA accepting the resubmission of its Biologics License Application for RP1, a melanoma treatment. Community members are actively discussing price target upgrades and the potential for a short squeeze, while also weighing the possibility of future dilution. The stock's movement is also being compared to other trending tickers in the sector.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending due to positive data released by partner GenFleet Therapeutics regarding their lung cancer drug GFH375, showing promising response rates in NSCLC patients. The community is discussing the potential implications of these results, including a possible short squeeze, buyout scenarios, and comparing VSTM to competitors like RVMD. There is optimism regarding upcoming catalysts, such as presentations, NCCN decisions, and potential partnerships.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

RAPT Therapeutics is trending following the announcement of positive topline data from its Phase 2 trial of RPT904 in Chronic Spontaneous Urticaria, leading to discussions about potential price targets and the strength of the biotech momentum. However, some community members are expressing concerns about potential offerings and drops, while others remain optimistic about the company's future and potential breakouts. The stock is also being mentioned in connection with other trending stocks and potential squeeze opportunities.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Corbus Pharmaceuticals Holdings Inc

CRBP is trending amid discussions of market manipulation and a significant drop from pre-market highs, despite recent analyst upgrades and price targets. The community is actively debating the impact of upcoming catalysts and data releases, particularly around CRB-701, while also noting the high institutional ownership and short interest. Overall, conversation is centered on the potential for a rebound following an overreaction to news in the broader sector, with some seeing it as a buying opportunity.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity (CELC) is trending following positive Phase 3 trial data for its breast cancer therapy, with the community actively discussing the potential for FDA approval and a possible buyout. The stock's significant pre-market surge has sparked conversations about its valuation and future prospects in the biotech sector. Community members are weighing the potential for continued gains against the possibility of a pullback.

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Exelixis is trending due to discussions around unusual options activity and potential bullish setups, including a possible short squeeze due to high short interest. Community members are also focused on the company's long-term potential, driven by its commercial product and pipeline updates, with some viewing it as a possible acquisition target. Recent analyst ratings and target price adjustments are contributing to the increased attention on the stock.

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp

BGLC is trending due to a recently announced strategic partnership term sheet, sparking excitement around potential growth. The community is actively discussing the company's low float and potential for a significant run, with some highlighting its past as a known runner. Community members also point to the company's Ethereum-focused treasury strategy as a potential catalyst.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix ($CRMD) is trending after reporting preliminary Q3 results and raising FY25 revenue guidance, leading to a surge in stock price. The community is actively discussing the company's profitability, potential for a short squeeze, and a possible acquisition by Pfizer. Positive real-world evidence and further catalysts are anticipated, while some investors express frustration with management decisions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Blue Owl Capital Hires Greg Porteous to Lead Defined Contribution Retirement Solutions

Blue Owl Capital Hires Greg Porteous to Lead Defined Contribution Retirement Solutions Blue Owl Capital Hires Greg Porteous to Lead Defined Contribution Retirement Solutions PR Newswire NEW YORK...

Blue Owl Capital's Packer: First Brands & Tricolor collapses were idiosyncratic, not broader risk

Craig Packer, co-president of Blue Owl Capital, joins CNBC's 'Money Movers' to discuss how investors should think about the collapse of First Brands and Tricolor, whether this has implications for...

Blue Owl Capital Launches TALON: A Tax Education Platform Empowering Financial Advisors in Private Markets

Blue Owl Capital Launches TALON: A Tax Education Platform Empowering Financial Advisors in Private Markets Blue Owl Capital Launches TALON: A Tax Education Platform Empowering Financial Advisors in...

PayPal's Buy Now Pay Later Grows Fast: What Drives This Surge? 

PYPL's BNPL jumped with 20% volume growth in Q2 2025. Its new financing from Blue Owl, big merchant wins, and its higher order value remain encouraging.

PayPal Holdings Inc. (PYPL) on Wednesday announced a multi-year deal with Blue Owl Capital Inc. (OWL) to sell nearly $7 billion of its buy now, pay later (BNPL) receivables originated in the U.S.According to the company’s announcement, funds managed by Blue Owl will purchase these BNPL receivables as part of a two-year agreement. PayPal stated it will continue to be responsible for all customer-facing activities, including underwriting and servicing, associated with its U.S. Pay in four BNPL products.<a href="https://stocktwits.com/symbol/PYPL">PayPal shares</a> were up 1% in Wednesday’s pre-market trading, while&nbsp;<a href="https://stocktwits.com/symbol/OWL">Blue Owl’s shares</a> were up more than 2%. Retail sentiment around PayPal was in the ‘extremely bullish’ territory, while it was ‘neutral’ for Blue Owl.“This transaction reflects our disciplined approach to capital allocation. Partnering with Blue Owl helps support the growth of our Pay Later portfolio and gives us greater ability to invest in our strategic initiatives and innovation,” said Jamie Miller, Chief Financial &amp; Operating Officer of PayPal.PayPal clarified that the transaction has already been considered in the company’s third-quarter and full-year 2025 guidance for earnings per share (EPS). It launched BNPL services in 2020, while consumer financing has been a part of its portfolio since 2008. PayPal stated that it processed $33 billion of BNPL payment volume globally, representing an approximately 21% increase from 2023.The company stated that customers who use BNPL services have an average order value that is 80% higher than that of a standard transaction. PayPal’s “Pay in 4” offers consumers&nbsp;the ability to pay for eligible purchases over four interest-free payments in six weeks.<a href="https://stocktwits.com/symbol/PYPL">PYPL stock</a> is down 21% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/OWL">OWL stock</a> is down 20%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-decline-as-jerome-powell-outlines-risks-ahead/chDK6sBR33E">Dow Futures Edge Lower As Investors Brace For Key Economic Data Releases This Week: BABA, MU, LAC, GM Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of PayPal Holdings Inc. 

PayPal Enters Multi-Year Deal With Blue Owl Capital For Nearly $7 Billion Buy Now, Pay Later Receivables

PayPal stated it will continue to be responsible for all customer-facing activities, including underwriting and servicing, associated with its U.S. Pay in four BNPL products.

Equity

Jim Cramer on Friday said that the data center story will get a boost following two major deals by Meta Platforms Inc. (META) and SoftBank Group Corp. (SFTBY).In a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/jimcramer/status/1953782992494567535">post</a> on X, the ‘Mad Money’ host sounded optimistic about Meta’s $29 billion deal with Pacific Investment Management Co. and Blue Owl Capital Inc. (OWL), and SoftBank’s acquisition of Apple supplier Foxconn’s Ohio plant.<figure class="image"><img style="aspect-ratio:587/177;" src="https://news.stocktwits-cdn.com/Jim_Cramer_post_jpg_0ee9fb86f2.webp" alt="Jim Cramer's post on X" width="587" height="177"><figcaption>Jim Cramer's post on X | @jimcramer/X</figcaption></figure>Meta has chosen Pacific Investment Management and Blue Owl Capital to lead a $29 billion financing round for its data center expansion plans, according to a Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-08/meta-picks-pimco-blue-owl-for-29-billion-data-center-financing">report</a>.<a href="https://stocktwits.com/symbol/META">Meta’s shares</a> traded 0.05% higher in Friday’s pre-market session. Stocktwits data showed the retail sentiment around the company on the platform was in the ‘bearish’ territory.According to the report, Pimco is expected to lead a $26 billion debt financing round for Meta’s data expansion efforts in Louisiana. The remaining $3 billion fundraising would be through the equity route, but final details are not known yet.Earlier on Friday, Masayoshi Son-led SoftBank acquired Foxconn’s Ohio plant, according to a Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-08/softbank-buys-foxconn-s-ohio-plant-to-jumpstart-stargate-ai-push">report</a>, as the company looks to push its $500 billion Stargate data center project announced earlier this year with OpenAI and Oracle Corp. (ORCL).The Foxconn plant in question is an electric vehicle facility, and the deal is valued at $375 million, according to the report.In March, during Nvidia Corp.’s (NVDA) annual GTC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://youtu.be/_waPvOwL9Z8">event</a>, CEO Jensen Huang said data center buildouts are expected to hit the $1 trillion mark by 2028.<a href="https://stocktwits.com/symbol/META">META’s stock</a> is up 30% year-to-date and 49% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-rise-as-wall-street-focuses-on-earnings/chrn9aLRdEV">Dow Futures Rise As Investors Shift Focus To Earnings: FLY, XYZ, SOUN, TTD Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jim Cramer discusses Twitter Inc.'s (TWTR) initial public offering (IPO) on the floor of the NYSE. 

Jim Cramer Says SoftBank’s Acquisition Of Foxconn’s Ohio Plant, Meta’s $29 Billion Pimco Deal Will Boost Data Center Story

Meta has reportedly chosen Pacific Investment Management and Blue Owl Capital to lead a $29 billion financing round for its data center expansion plans.

Blue Owl Capital Inc. (OWL) Meets Q2 Earnings Estimates

Blue Owl Capital (OWL) delivered earnings and revenue surprises of 0.00% and +1.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

T. Rowe Price (TROW) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

T. Rowe (TROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Blue Owl Capital Inc. (OWL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Blue Owl Capital (OWL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Voya Tap Into New Growth Opportunities Through Blue Owl Alliance?

VOYA teams up with Blue Owl to bring private market strategies to retirement plans, aiming to boost diversification and long-term outcomes.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

OWL
Blue Owl Capital Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OWL News

OWLBlue Owl Capital Inc - Ordinary Shares - Class A